SynthesisJournal of robotic surgery2020
Port-site metastasis and atypical recurrences after robotic-assisted radical cystectomy (RARC): an updated comprehensive and systematic review of current evidences.
Synthesis in Journal of robotic surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot-Assisted Radical Cystectomy for Advanced Bladder Cancer.IJU case reports · 2026Article
- Port-Site Seeding of Urothelial Carcinoma After Robotic-Assisted Radical Prostatectomy Accompanied With Elevated Serum Levels of Carbohydrate Antigen 19-9: A Case Report.Case reports in urology · 2026Article
- Absence of bladder cancer cells in surgical smoke from robot-assisted radical cystectomy: a prospective study.Frontiers in urology · 2026Article
- Single-port robotic pyeloplasty in young patients: cosmetic satisfaction and faster recovery matter.Journal of robotic surgery · 2025Article
- Robotic-assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes.BJUI compass · 2024Review
- Early port site and peritoneal metastasis following robot-assisted radical cystectomy: a rare case report.Journal of cancer research and clinical oncology · 2024Article
- Images in urology - Metastatic urothelial carcinoma of the right vastus lateralis following robotic-assisted radical cystectomy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Robotic-assisted laparoscopy in pediatric surgical oncology: a narrative review.Translational pediatrics · 2023Review
- Robot-Assisted Radical Cystectomy: A Single-Center Experience and a Narrative Review of Recent Evidence.Diagnostics (Basel, Switzerland) · 2023Article
- Robotics-Assisted Pediatric Oncology Surgery-A Preliminary Single-Center Report and a Systematic Review of Published Studies.Frontiers in pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this systematic review is to evaluate the current evidence regarding atypical metastases in patients undergoing robotic-assisted radical cystectomy (RARC). A review of the current literature was conducted through the Medline and NCBI PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar databases in October 2019. From the literature search using the cited keys and after a careful evaluation of the full texts, we included 31 articles in the study. Fourteen studies (45.2%) reported at least an atypical recurrence during the follow-up period with a rate between 4 and 40% of all the recurrences. Overall, 105 (1.63%) of the 6720 patients who have been evaluated in the included studies developed an atypical recurrence. Sixty-three (60%) of these atypical metastases were peritoneal carcinomatosis, 16 (15.2%) extrapelvic lymph nodes metastases, 11 (10.5%) port-site metastases, 10 (9.5%) retroperitoneal nodal metastases, while 5 (3.8%) patients developed more than one type of atypical recurrence. In literature, there is a low but not negligible incidence of atypical recurrences after RARC. However, publication bias and retrospective design of most studies could influence the evidences. Further prospective randomized studies are needed to clarify the real risk of patients undergoing RARC to develop atypical metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.